Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections
用于副流感和人类偏肺病毒感染吸入治疗的工程化“粘膜捕获”抗体
基本信息
- 批准号:10587723
- 负责人:
- 金额:$ 68.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-19 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAffinityAirAntibodiesApicalBackBindingBiological AssayBloodBronchiolitisCaringCellsChildClinicalCytopathologyDiffuseDoseEbolaElderlyEngineeringEpithelialEvaluationFunctional disorderGoalsHamstersHerpesvirus 1HistologyHourHumanHuman MetapneumovirusImmuneImmunocompromised HostImmunoglobulin GImmunotherapyIn VitroIndividualInfantInfectionInflammationInfluenzaInhalationInhalation TherapyInterceptInterventionLeadLibrariesLife Cycle StagesLiquid substanceLower Respiratory Tract InfectionLungMedicalMetapneumovirusMethodsModelingMonoclonal AntibodiesMucinsMucociliary ClearanceMucous MembraneMucous body substanceMusNebulizerNeonatalNeutrophil InfiltrationNoseParainfluenzaParticulatePathologicPathologyPatientsPharmacologyPneumoniaPolysaccharidesProliferatingPropertyProphylactic treatmentProteinsRecombinantsResearch PersonnelRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsRespiratory syncytial virusStructure of parenchyma of lungSurfaceTissuesVaccinesVaginaViralViral Load resultViral load measurementViremiaVirionVirusVirus SheddingWorkYeastsairway epitheliumantibody engineeringantigen bindingasthma exacerbationbasecrosslinkeffective therapyefficacy testingimprovedin vitro Modelin vivoin vivo Modelmolecular targeted therapiesneutralizing monoclonal antibodiesnovelparainfluenza viruspathogenpurgerespiratoryrespiratory virustransmission processviral RNA
项目摘要
Human parainfluenza virus (PIV) and metapneumovirus (MPV) are common causes of lower respiratory
tract infections in infants and young children, and major causes of respiratory illness in immune compromised
adults and the elderly. Unfortunately, there are no therapy or vaccine for either viruses, and only supportive
medical care is available. Interestingly, PIV and MPV share many pathological and clinical manifestations as
Respiratory Syncytial Virus (RSV). Indeed, neither PIV nor MPV are known to cause viremia in the blood of
infected patients, indicating both infections are strictly localized in the airways similar to RSV that shed progeny
viruses exclusively from the apical surface of infected cells. Such unique pathophysiology implies progeny
viruses must traverse airway mucus (AM) before spreading to neighboring cells. This in turn motivated us to
develop a pathogen-specific antiviral that could physically limit the spread of the infections within the airways.
We recently discovered a novel Ab effector function in mucus – trapping individual pathogens in mucus
based on carefully-tuned affinity between IgG-Fc and mucins – and developed a platform for enhancing mAb
function at mucosal surfaces. We hypothesize that “muco-trapping” mAb delivered to the airways can directly
intervene with the viral life cycle by intercepting and trapping shed progeny viruses in AM, rapidly eliminate
trapped viruses from the airways by natural mucociliary clearance, and enable effective therapy in vivo. In
support of this strategy, we engineered mAbs that potently trap RSV in AM, and showed that nebulized
delivery of “muco-trapping” mAb to RSV-infected neonatal lambs beginning on Day 3 post infection effectively
reduced the infectious viral load in lung tissues to non-detectible levels within 3 days, with viral RNA in
bronchial tissues reduced by 11-fold compared to vehicle control. These results motivated us to explore
whether a similar approach may be effective in treating PIV and MPV infections. In support of this application,
we have engineered antibodies with picomolar affinity to diverse strains of both viruses, and demonstrated that
we could effectively trap viruses in human AM and limit spread of infection in vitro in well-differentiated human
airway epithelium (WD-HAE) grown at the air-liquid interface.
In this proposal, we will continue our work with affinity maturation using mammalian and yeast display
to produce high affinity mAb that broadly bind and neutralize diverse strains of PIV and MPV (Aim 1). We will
validate whether these mAbs can trap PIV and MPV in fresh undiluted human AM, and whether they can inhibit
the spread of pre-established PIV and MPV infections in WD-HAE cultures (Aim 2). We will then advance the
lead mAb for both viruses for evaluation in a hamster nasal infection model (Aim 3). By enabling enhanced
mAb function in mucus secretions, we expect we will help pave the way for improved, molecularly-targeted
therapies and prophylaxis against a broad spectrum of pathogens across all major mucosal surfaces, providing
a powerful option addressing the current gap in pharmacological interventions for respiratory infections.
人类副流感病毒(PIV)和偏肺病毒(MPV)是下呼吸道感染的常见原因
婴儿和幼儿的呼吸道感染以及免疫受损者呼吸道疾病的主要原因
成人和老年人。不幸的是,这两种病毒都没有治疗方法或疫苗,只能提供支持性治疗
提供医疗服务。有趣的是,PIV 和 MPV 有许多共同的病理和临床表现:
呼吸道合胞病毒(RSV)。事实上,目前已知 PIV 和 MPV 均不会导致血液中的病毒血症。
感染患者,表明这两种感染都严格局限于呼吸道,与传播后代的 RSV 类似
病毒仅来自受感染细胞的顶端表面。这种独特的病理生理学意味着后代
病毒在传播到邻近细胞之前必须穿过气道粘液(AM)。这反过来又促使我们
开发一种病原体特异性抗病毒药物,可以从物理上限制呼吸道内感染的传播。
我们最近在粘液中发现了一种新的抗体效应器功能——将单个病原体捕获在粘液中
基于 IgG-Fc 和粘蛋白之间精心调整的亲和力 – 并开发了一个增强 mAb 的平台
作用于粘膜表面。我们假设递送至气道的“粘膜捕获”单克隆抗体可以直接
通过拦截和捕获 AM 中脱落的后代病毒来干预病毒生命周期,快速消灭
通过自然粘膜纤毛清除作用捕获气道中的病毒,并实现体内有效治疗。在
为了支持这一策略,我们设计了可有效捕获 AM 中 RSV 的 mAb,并表明雾化
从感染后第 3 天开始,向感染 RSV 的新生羔羊有效输送“粘膜捕获”单克隆抗体
3天内将肺组织中的感染性病毒载量降低至不可检测的水平,其中病毒RNA
与载体对照相比,支气管组织减少了 11 倍。这些结果激励我们去探索
类似的方法是否可以有效治疗 PIV 和 MPV 感染。为了支持这个申请,
我们设计了对两种病毒的不同毒株具有皮摩尔亲和力的抗体,并证明
我们可以有效地捕获人类AM中的病毒,并限制高分化人类体外感染的传播
气道上皮(WD-HAE)在气液界面生长。
在本提案中,我们将继续利用哺乳动物和酵母展示进行亲和力成熟的工作
产生可广泛结合并中和 PIV 和 MPV 不同毒株的高亲和力 mAb(目标 1)。我们将
验证这些 mAb 是否可以捕获新鲜未稀释的人 AM 中的 PIV 和 MPV,以及是否可以抑制
WD-HAE 培养物中预先确定的 PIV 和 MPV 感染的传播(目标 2)。然后我们将推进
两种病毒的先导单克隆抗体,用于在仓鼠鼻部感染模型中进行评估(目标 3)。通过启用增强
mAb 在粘液分泌物中发挥作用,我们希望能够帮助为改进的分子靶向治疗铺平道路
针对所有主要粘膜表面的广谱病原体的治疗和预防,提供
这是解决当前呼吸道感染药物干预措施空白的有力选择。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Samuel Lai其他文献
Samuel Lai的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Samuel Lai', 18)}}的其他基金
Engineering Siglec15/TGF-beta targeted bispecific antibodies that modulate the tumor microenvironment and enhances T-cell immunotherapy against pancreatic cancer
工程化 Siglec15/TGF-β 靶向双特异性抗体可调节肿瘤微环境并增强针对胰腺癌的 T 细胞免疫治疗
- 批准号:
10651442 - 财政年份:2023
- 资助金额:
$ 68.84万 - 项目类别:
Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections
用于副流感和人类偏肺病毒感染吸入治疗的工程化“粘膜捕获”抗体
- 批准号:
10707403 - 财政年份:2022
- 资助金额:
$ 68.84万 - 项目类别:
Engineering bispecific antibodies for non-hormonal contraception
用于非激素避孕的双特异性抗体工程
- 批准号:
10428467 - 财政年份:2020
- 资助金额:
$ 68.84万 - 项目类别:
Engineering bispecific antibodies for non-hormonal contraception
用于非激素避孕的双特异性抗体工程
- 批准号:
10618849 - 财政年份:2020
- 资助金额:
$ 68.84万 - 项目类别:
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics
克服抗 PEG 免疫,恢复 PEG 化治疗的延长循环和功效
- 批准号:
10181024 - 财政年份:2018
- 资助金额:
$ 68.84万 - 项目类别:
Artificial neural networks for high performance, fully automated particle tracking analysis even at low signal-to-noise regimes
人工神经网络即使在低信噪比条件下也能实现高性能、全自动粒子跟踪分析
- 批准号:
9347679 - 财政年份:2017
- 资助金额:
$ 68.84万 - 项目类别:
Prevalence and characteristics of anti-PEG antibodies in humans
人类抗 PEG 抗体的流行率和特征
- 批准号:
8622684 - 财政年份:2014
- 资助金额:
$ 68.84万 - 项目类别:
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus
优化 Plantibodies 以捕获宫颈阴道粘液中的 HIV 和 HSV
- 批准号:
8803845 - 财政年份:2014
- 资助金额:
$ 68.84万 - 项目类别:
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus
优化 Plantibodies 以捕获宫颈阴道粘液中的 HIV 和 HSV
- 批准号:
8515320 - 财政年份:2013
- 资助金额:
$ 68.84万 - 项目类别:
Trapping HIV in mucus with IgG antibodies
用 IgG 抗体将 HIV 捕获在粘液中
- 批准号:
8208988 - 财政年份:2011
- 资助金额:
$ 68.84万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 68.84万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 68.84万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 68.84万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 68.84万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 68.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 68.84万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 68.84万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 68.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 68.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 68.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)